Continuous Glucose Monitoring Adoption in the United Kingdom – An Economic and Policy Perspective
Continuous glucose monitoring (CGM) technology provides real-time glucose concentration data to people with diabetes. The data enable timely treatment decisions that can lead to avoidance or mitigation of hypoglycaemia, with potential cost savings. This commentary discusses CGM implementation and funding policies in the UK, and regional disparities that confront many people with diabetes who could benefit from the technology.
Continuous glucose monitoring,
Nick Oliver has received research
support from Dexcom, Inc. This article is a short
opinion piece and has not been submitted to
external peer reviewers, but was reviewed by the
editorial board for accuracy before publication.
Nick Oliver, Section of
Diabetes, Endocrinology and Metabolism, Faculty of
Medicine, Imperial College, Du Cane Road, London,
W12 0HS, UK. E: Nick.firstname.lastname@example.org
The publication of this article was
supported by Dexcom, Inc. The views and opinions
expressed are those of the author and do not
necessarily reflect those of Dexcom, Inc.
Open Access: This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any non-commercial use, distribution,
adaptation and reproduction provided the original.
Share this Article
Related Content In Diabetes
Foreword: touchREVIEWS in Endocrinology 19.1
Welcome to the latest edition of touchREVIEWS in Endocrinology. In this edition we feature a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We start with a focus on diabetes. An editorial from Bhattacharya and Kalra gives an overview of the […]
Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
touchREVIEWS in Endocrinology. 2023;19(1):38-45
The incidence of youth-onset type 2 diabetes (T2D) is increasing.1,2 Growing evidence has demonstrated that youth-onset T2D is rapidly progressive, with earlier onset of life-limiting complications compared with adult-onset T2D.3,4 Initiation of effective treatment that can restore beta cell function is critical. Until 2019, metformin and insulin were the only medications approved by the United States […]
Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer’s Disease
touchREVIEWS in Endocrinology. 2023;19(1):16-24
Type 2 diabetes (T2DM) is a disease with a complex aetiopathogenesis that leads to a wide variety of metabolic disorders. This includes, by definition, high plasma glucose levels, but also elevated blood pressure, dyslipidaemia, cardiorenal complications and strokes. All of these disorders, beyond the progressive beta cell failure, derive from insulin resistance (IR).1 Among the many […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!